Telo Genomics Announces the Final Assignment of Patents on Hematological Cancers, Liquid Biopsy and Alzheimer’s Disease

TORONTO, Nov. 11, 2020 (GLOBE NEWSWIRE) — Telo Genomics Corp. (TSX-V: TELO) (the “Company” or “TELO”) is pleased to announce that it has received final approval and grant of three of its pending patent applications including:
Diagnostic Methods for Hematological Disorders (Hematological Cancers) – CanadaMethods for Characterizing and isolating circulating tumor cell subpopulations (Liquid biopsy) – CanadaMethods of Diagnosing Alzheimer’s Disease – Europe
TELO has already been granted final patents governing its intellectual property (“IP”) for hematological cancers in the USA, and Alzheimer’s Disease in the USA and Canada. TELO’s patent application on liquid biopsy in the USA is still pending.TELO has secured intellectual property protection in various jurisdictions around the world and owns a portfolio of patents and pending patent applications in the United States, Canada and the EU. The scope of the IP covers its core technology and specific applications of the technology. In addition to the patents and pending patent applications, TeloView® is protected as a trademark in the USA, Canada, Europe and Israel.“The issuance of three additional final patents further augments TELO’s already strong IP portfolio,” said Sabine Mai, TELO Director, and Chair of the Clinical and Scientific Advisory Board. “Blood cancers and liquid biopsy are at the core of the Company’s commercialization program. The issuance of these patents assures the long-term protection of the TeloView® platform as a prognostic/diagnostic tool for these diseases.”The Company would also like to announce that pursuant to its press release dated October 21st, 2020, Leede Jones Gable Inc. and Mackie Research Corp. have exercised 5,026,800 of clients and broker warrants for gross proceeds of $944,180. As a result, neither Leede nor Mackie will be soliciting further warrant exercises going forward.About Telo GenomicsTelo Genomics is a biotech company pioneering the most comprehensive telomere platform in the industry with powerful applications and prognostic solutions. These include liquid biopsies and related technologies in oncology and neurological diseases. Liquid biopsy is a rapidly growing field of significant interest to the medical community for being less invasive and more easily replicated than traditional diagnostic approaches. By combining our team’s considerable expertise in quantitative analysis of 3D telomeres with molecular biology and artificial intelligence to recognize disease-associated genetic instability, Telo Genomics is developing simple and accurate products that improve day-to-day care for patients by serving the needs of pathologists, clinicians, academic researchers and drug developers. The benefits of our proprietary technology have been substantiated in over 150 peer reviewed publications and in 25 clinical studies involving more than 3,000 patients with multiple cancers and Alzheimer’s disease. Our lead application, Telo-MM is being developed to provide important, actionable information to medical professionals in the treatment of Multiple Myeloma, a deadly form of blood cancer. For more information please visit www.telodx.com.For further information, please contact:Hugh Rogers
Director
416-673-8487
[email protected]
MaRS Centre, South Tower, 101 College Street, Suite 200, Toronto, ON, M5G 1L7
www.telodx.com
Neither the TSX Venture Exchange nor its Regulation Services Provider (as such term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.Cautionary Note Regarding Forward-Looking StatementsCertain information contained herein may constitute “forward-looking information” under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “intends”, “will”, or variations of such words and phrases or statements that certain actions, events or results “will” occur. Forward-looking statements regarding the clinical efficacy of products, commercial viability of products, use of proceeds, and the ability of the TeloViewTMplatform to deliver personalized medicine resulting in better treatments and outcomes are based on the Company’s estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information, including capital expenditures and other costs. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. The Company will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws.

Resource News, Oil and Gas News, Mining News, Renewable News

Resource News

Oil, Gas, Mining & Metals

Start typing and press Enter to search

shares